New drug ProAgio enters human testing for Tough-to-Treat pancreatic cancer
NCT ID NCT05085548
Summary
This is the first human study to test the safety of an experimental drug called ProAgio in people with advanced solid tumors, including pancreatic cancer, that have stopped responding to standard treatments. The main goal is to find a safe dose for future studies by giving ProAgio to small groups of patients at increasing amounts. Researchers will also gather early information on whether the drug shows any signs of helping to control the cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMOR MALIGNANCIES are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
National Cancer Institute
Bethesda, Maryland, 20892, United States
Conditions
Explore the condition pages connected to this study.